Meeting reportNMDA receptor involvement in two animal models of Parkinson's disease
References (11)
- et al.
Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
Neurosci. Lett.
(1985) - et al.
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
Life Sci.
(1985) - et al.
The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death
Ann. Rev. Neurosci.
(1990) - et al.
Abnormalities of the electron transport chain in idiopathic Parkinson's disease
Ann Neurol.
(1989) - et al.
Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity
Science
(1989)
Cited by (13)
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
2000, Progress in NeurobiologyCitation Excerpt :Glutamate neurotransmission plays an integral role in basal ganglia functioning especially in the striatum, where the balance of glutamate and dopamine is critical but also in the substantia nigra which receives glutamatergic input from the subthalamic nucleus and cortex (for review see: Blandini and Greenamyre, 1998; Rodriguez et al., 1998). Nigral dopaminergic neurons possess glutamate receptors (Difazio et al., 1992; Christoffersen and Meltzer, 1995; Kosinski et al., 1998) and they degenerate when exposed to excitotoxins (Zeevalk et al., 1994; Connop et al., 1995; Miranda et al., 1999). Neuroprotection from MPTP toxicity to dopaminergic neurons is afforded by treatment with excitotoxin antagonists, especially those for the NMDA receptor or its modulatory glycine site (Turski et al., 1991; Storey et al., 1992; Brouillet and Beal, 1993; Kanthasamy et al., 1997; for review see Ossowska, 1994) including in primates where parkinsonian symptoms are also ameliorated (Zuddas et al., 1992; Lange et al., 1993).